• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分化型甲状腺癌患者非同步第二原发恶性肿瘤及相关死亡的危险因素。

Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma.

机构信息

Division of Endocrine Surgery, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.

出版信息

Ann Surg Oncol. 2011 Dec;18(13):3559-65. doi: 10.1245/s10434-011-1777-1. Epub 2011 May 15.

DOI:10.1245/s10434-011-1777-1
PMID:21573833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3222830/
Abstract

BACKGROUND

Differentiated thyroid cancer (DTC) survivors are at increased risk of developing nonsynchronous second primary malignancy (NSPM). This study aims to examine possible risk factors leading to occurrence of NSPM as well as risk factors leading to NSPM-related death in patients with DTC.

METHODS

Of the 1,106 patients with DTC managed at our institution, 92 (8.3%) patients developed NSPM and 40 (3.6%) patients died of NSPM. All causes of death were confirmed by medical record, autopsy report or death certificate. Clinicopathological variables were compared between those without NSPM and with NSPM as well as between those who died of NSPM and did not die of NSPM. Significant variables on univariate analysis were entered into a Cox proportional hazards model.

RESULTS

The median latency period from diagnosis of DTC to NSPM was 142.7 (range 16.8-511.0) months. For occurrence of NSPM, age at DTC diagnosis ≥50 years old [relative risk (RR) = 2.35], cumulative radioactive iodine (RAI) activity 3.0-8.9 GBq (RR = 2.38), and external local radiotherapy (ERT) (RR = 1.95) were significant risk factors. For NSPM-related death, age at DTC diagnosis ≥50 years old (RR = 3.32) and nonbreast cancer (RR = 5.76) were significant risk factors.

CONCLUSIONS

NSPM accounted for 18.7% of all deaths in DTC, but mortality was high (43.5%). Age at DTC diagnosis ≥50 years old, cumulative RAI activity 3.0-8.9 GBq, and ERT were significant risk factors for occurrence of NSPM, whereas age at DTC diagnosis ≥50 years old and the diagnosis of nonbreast cancer were significant risk factors for NSPM-related death.

摘要

背景

分化型甲状腺癌(DTC)幸存者发生非同步第二原发恶性肿瘤(NSPM)的风险增加。本研究旨在探讨导致 DTC 患者发生 NSPM 的可能危险因素,以及导致与 NSPM 相关的死亡的危险因素。

方法

在我院治疗的 1106 例 DTC 患者中,92 例(8.3%)发生 NSPM,40 例(3.6%)死于 NSPM。所有死因均经病历、尸检报告或死亡证明证实。比较无 NSPM 与有 NSPM 的患者、以及死于 NSPM 与未死于 NSPM 的患者的临床病理变量。单因素分析中有意义的变量被纳入 Cox 比例风险模型。

结果

从 DTC 诊断到 NSPM 的中位潜伏期为 142.7(范围 16.8-511.0)个月。对于 NSPM 的发生,DTC 诊断时年龄≥50 岁[相对风险(RR)=2.35]、累积放射性碘(RAI)活度 3.0-8.9GBq(RR=2.38)和外部局部放疗(ERT)(RR=1.95)是显著的危险因素。对于与 NSPM 相关的死亡,DTC 诊断时年龄≥50 岁(RR=3.32)和非乳腺癌(RR=5.76)是显著的危险因素。

结论

NSPM 占 DTC 所有死亡的 18.7%,但死亡率较高(43.5%)。DTC 诊断时年龄≥50 岁、累积 RAI 活度 3.0-8.9GBq 和 ERT 是发生 NSPM 的显著危险因素,而 DTC 诊断时年龄≥50 岁和诊断为非乳腺癌是与 NSPM 相关的死亡的显著危险因素。

相似文献

1
Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma.分化型甲状腺癌患者非同步第二原发恶性肿瘤及相关死亡的危险因素。
Ann Surg Oncol. 2011 Dec;18(13):3559-65. doi: 10.1245/s10434-011-1777-1. Epub 2011 May 15.
2
Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.评估伴有远处转移的分化型甲状腺癌患者与癌症特异性生存相关的预后因素。
Ann Surg Oncol. 2013 Apr;20(4):1329-35. doi: 10.1245/s10434-012-2711-x. Epub 2012 Oct 28.
3
Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.术后放射性碘与外照射治疗 IV 期分化型甲状腺癌的生存结局比较。
Thyroid. 2017 Jul;27(7):944-952. doi: 10.1089/thy.2016.0650. Epub 2017 May 17.
4
Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.放射性碘治疗分化型甲状腺癌后的第二原发恶性肿瘤风险。
Surgery. 2012 Jun;151(6):844-50. doi: 10.1016/j.surg.2011.12.019. Epub 2012 Feb 15.
5
The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq.累积碘-131剂量超过37GBq的分化型甲状腺癌患者发生第二原发性恶性肿瘤的风险增加。
Clin Endocrinol (Oxf). 2015 Jul;83(1):117-23. doi: 10.1111/cen.12581. Epub 2014 Oct 10.
6
Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.分化型甲状腺癌放射性碘治疗后发生第二原发性恶性肿瘤的风险。
Ann Otol Rhinol Laryngol. 2006 Aug;115(8):607-10. doi: 10.1177/000348940611500806.
7
Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.放射性碘对低危分化型甲状腺癌患者总生存的影响。
J Clin Endocrinol Metab. 2012 May;97(5):1526-35. doi: 10.1210/jc.2011-2512. Epub 2012 Feb 16.
8
Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival.放射性诱导的分化型甲状腺癌与总体生存率提高相关,但与甲状腺癌特异性死亡率或无病生存率无关。
Thyroid. 2016 Aug;26(8):1053-60. doi: 10.1089/thy.2015.0634.
9
Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer.预测分化型甲状腺癌相关死亡率的最佳截断年龄
PLoS One. 2015 Jun 23;10(6):e0130848. doi: 10.1371/journal.pone.0130848. eCollection 2015.
10
Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.第二原发恶性肿瘤对分化型甲状腺癌结局的影响。
Surgery. 2010 Dec;148(6):1191-6; discussion 1196-7. doi: 10.1016/j.surg.2010.09.022.

引用本文的文献

1
Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies.通过倾向评分匹配进行甲状腺癌的对比分析:揭示多种恶性肿瘤的影响。
Front Endocrinol (Lausanne). 2024 Jun 4;15:1366935. doi: 10.3389/fendo.2024.1366935. eCollection 2024.
2
Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.多激酶抑制剂/仑伐替尼在同时性/异时性合并放射性抵抗分化型甲状腺癌的癌症患者中的应用。
Cancer Med. 2022 Oct;11 Suppl 1(Suppl 1):26-32. doi: 10.1002/cam4.5107.
3
Non-thyroidal second primary malignancy in papillary thyroid cancer patients.甲状腺乳头状癌患者的非甲状腺第二原发性恶性肿瘤
Eur Thyroid J. 2022 Jul 19;11(4). doi: 10.1530/ETJ-22-0018. Print 2022 Aug 1.
4
Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators.分化型甲状腺癌与第二原发性恶性肿瘤的同时发生:与错配修复蛋白和细胞周期调节因子表达谱的相关性
Cancers (Basel). 2021 Oct 31;13(21):5486. doi: 10.3390/cancers13215486.
5
Analysis of overall survival in differentiated thyroid cancer patients with double primary malignancy.分化型甲状腺癌合并双原发恶性肿瘤患者的总生存分析。
Kaohsiung J Med Sci. 2021 Jan;37(1):63-71. doi: 10.1002/kjm2.12286. Epub 2020 Aug 25.
6
How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules.甲状腺结节患者管理中如何处理临界性/前驱性甲状腺肿瘤。
Gland Surg. 2018 Aug;7(Suppl 1):S8-S18. doi: 10.21037/gs.2017.08.02.
7
Is prophylactic central neck dissection necessary for cN0 differentiated thyroid cancer patients at initial treatment? A meta-analysis of the literature.对于初始治疗的cN0分化型甲状腺癌患者,预防性中央区颈部淋巴结清扫是否必要?一项文献荟萃分析。
Acta Otorhinolaryngol Ital. 2017 Feb;37(1):1-8. doi: 10.14639/0392-100X-1195.
8
Nonoperative management of low-risk differentiated thyroid carcinoma.低风险分化型甲状腺癌的非手术治疗
Curr Opin Oncol. 2015 Jan;27(1):15-20. doi: 10.1097/CCO.0000000000000143.
9
Secondary malignancy in patients with sporadic neuroendocrine neoplasia.散发性神经内分泌肿瘤患者的继发性恶性肿瘤。
Endocrine. 2013 Oct;44(2):510-6. doi: 10.1007/s12020-013-9911-4. Epub 2013 Mar 14.
10
Long-term survival in young women: hazards and competing risks after thyroid cancer.年轻女性的长期生存:甲状腺癌后的风险与竞争风险
J Cancer Epidemiol. 2012;2012:641372. doi: 10.1155/2012/641372. Epub 2012 Oct 2.

本文引用的文献

1
Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.第二原发恶性肿瘤对分化型甲状腺癌结局的影响。
Surgery. 2010 Dec;148(6):1191-6; discussion 1196-7. doi: 10.1016/j.surg.2010.09.022.
2
Impact of age, sex, and comorbidity on cancer therapy and disease progression.年龄、性别和合并症对癌症治疗和疾病进展的影响。
J Clin Oncol. 2010 Sep 10;28(26):4086-93. doi: 10.1200/JCO.2009.27.0579. Epub 2010 Jul 19.
3
Time course of risk factors in cancer etiology and progression.癌症病因学和进展中风险因素的时程变化。
J Clin Oncol. 2010 Sep 10;28(26):4052-7. doi: 10.1200/JCO.2009.26.9324. Epub 2010 Jul 19.
4
Treatment options for surgically resectable gastric cancer.手术可切除胃癌的治疗选择。
Curr Treat Options Oncol. 2010 Jun;11(1-2):14-23. doi: 10.1007/s11864-010-0117-1.
5
Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008.215 例儿童和青少年甲状腺乳头癌患者的长期预后:1940 年至 2008 年的治疗结果。
World J Surg. 2010 Jun;34(6):1192-202. doi: 10.1007/s00268-009-0364-0.
6
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.美国甲状腺协会修订的甲状腺结节和分化型甲状腺癌患者管理指南。
Thyroid. 2009 Nov;19(11):1167-214. doi: 10.1089/thy.2009.0110.
7
High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders.患有恶性和良性甲状腺肿瘤或肿瘤样疾病的患者中,同时性或异时性乳腺癌的发病率较高。
Anticancer Res. 2009 May;29(5):1607-10.
8
Thyroid cancer incidence and socioeconomic indicators of health care access.甲状腺癌发病率与医疗保健可及性的社会经济指标。
Cancer Causes Control. 2008 Aug;19(6):585-93. doi: 10.1007/s10552-008-9122-0. Epub 2008 Feb 1.
9
The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.分化型甲状腺癌治疗后长达三十年发生第二原发性恶性肿瘤的风险。
J Clin Endocrinol Metab. 2008 Feb;93(2):504-15. doi: 10.1210/jc.2007-1154. Epub 2007 Nov 20.
10
Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.甲状腺癌幸存者的第二原发性恶性肿瘤风险:一项系统综述和荟萃分析。
Thyroid. 2007 Dec;17(12):1277-88. doi: 10.1089/thy.2007.0171.